Liver X receptor β in the hippocampus: A potential novel target for the treatment of major depressive disorder?
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Neuropharmacology
- Vol. 135, 514-528
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81171237, 30600610, 81401109)
This publication has 72 references indexed in Scilit:
- Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant propertiesMolecular Psychiatry, 2013
- Neuronal circuitry mechanism regulating adult quiescent neural stem-cell fate decisionNature, 2012
- Liver X receptor biology and pharmacology: new pathways, challenges and opportunitiesTrends in Pharmacological Sciences, 2012
- Major depressive disorder: new clinical, neurobiological, and treatment perspectivesThe Lancet, 2012
- The neurobiology of anhedonia and other reward-related deficitsTrends in Neurosciences, 2012
- Leptin restores adult hippocampal neurogenesis in a chronic unpredictable stress model of depression and reverses glucocorticoid-induced inhibition of GSK-3β/β-catenin signalingMolecular Psychiatry, 2011
- Adult Neurogenesis in the Mammalian Brain: Significant Answers and Significant QuestionsNeuron, 2011
- A Meta-Analysis of Cytokines in Major DepressionBiological Psychiatry, 2010
- Treatment of Stroke with a Synthetic Liver X Receptor Agonist, TO901317, Promotes Synaptic Plasticity and Axonal Regeneration in MiceJournal of Cerebral Blood Flow & Metabolism, 2009
- Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major DepressionBiological Psychiatry, 2009